Metrics to compare | OSTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOSTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.1x | −8.4x | −0.4x | |
PEG Ratio | 0.10 | −0.31 | 0.00 | |
Price/Book | −7.1x | 4.9x | 2.6x | |
Price / LTM Sales | - | 4.6x | 3.0x | |
Upside (Analyst Target) | 345.0% | 50.7% | 56.5% | |
Fair Value Upside | Unlock | −8.3% | 8.5% | Unlock |
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company’s pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.